Class summary at a glance.

Every drug in the beta3-Adrenergic Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $5.05Bcombined across class
Total Rx claims: 7.8M2.2M unique beneficiaries
Generic mfrs (active): 6across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Mirabegron

Brand: Mirabgeorn · 5.6M Part D claims (CY24) · 1.6M beneficiaries · First FDA approval: 2012-06-28

6 generic mfrs 0 plans require PA

Low NADAC$2.21

→

Avg plan cost$10.59

Part D spend $3.59B 5× spread, current vs floor

Class share

71%

of class CY24 spend

View profile →

Vibegron

Brand: GEMTESA · 2.2M Part D claims (CY24) · 594K beneficiaries · First FDA approval: 2020-12-29

Brand-only (no generics) 2 plans require PA

Low NADAC$16.47

→

Avg plan cost$16.47

Part D spend $1.46B 1× spread, current vs floor

Class share

29%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.